EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity

Jiahua Zhang iD, Jintao Wei, Weiwen Lai, Jiawei Sun, Yan Bai, Hua Cao, Jiao Guo, Zhengquan Su iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041651 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jiahua Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Na…. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide 1, Anti-Obesity Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Program of Guangzhou, China, Guangdong Demonstration Base for Joint Cultivation of Postgraduates, Science Foundation for Distinguished Young Scholars of Guangdong, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is closely related to metabolic diseases, which brings a heavy burden to the health care system. It is urgent to formulate and implement effective treatment strategies. Glucagon-like peptide-1 (GLP-1) is a protein with seven transmembrane domains connected by type B and G proteins, which is widely distributed and expressed in many organs and tissues. GLP-1 analogues can reduce weight, lower blood pressure, and improve blood lipids. Obesity, diabetes, cardiovascular diseases, and other diseases have caused scientists’ research and development boom. Among them, GLP-1R agonist drugs have developed rapidly in weight-loss drugs. In this paper, based on the target of GLP-1, the mechanism of action of GLP-1 in obesity treatment was deeply studied, and the drugs approved and designed for obesity treatment based on GLP-1 target were elaborated in detail. Innovatively put forward and summarized the double and triple GLP-1 targeted drugs in the treatment of obesity with better effects and less toxic and side effects, and this can make full use of multi-target methods to treat other diseases in the future. Finally, it is pointed out that intestinal flora and microorganisms have many benefits in the treatment of obesity, and fecal bacteria transplantation may be a potential treatment for obesity with less harm to the body. This article provides some promising methods to treat obesity, which have strong practical value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like Peptide 1Anti-Obesity AgentsHumansAnimalsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

double and triple glucagon-like peptide-1 (GLP-1) targeted drugsfecal bacteria transplantation (FMT)gastric inhibitory peptidehypothalamusobesity

Substanzen

Glucagon-Like Peptide 1Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzh…
  • Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Disease…
  • School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China.
  • School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.

ORCID-Profile: Jiahua Zhang, Zhengquan Su

Förderung

  • Science and Technology Program of Guangzhou, China
  • Guangdong Demonstration Base for Joint Cultivation of Postgraduates
  • Science Foundation for Distinguished Young Scholars of Guangdong, China

Zitieren

APA

Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025). Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041651

Vancouver

Zhang J, Wei J, Lai W, Sun J, Bai Y, Cao H, et al. Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041651

BibTeX
@article{Zhang2025,
  author = {Zhang, Jiahua and Wei, Jintao and Lai, Weiwen and Sun, Jiawei and Bai, Yan and Cao, Hua and Guo, Jiao and Su, Zhengquan},
  title = {Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041651}
}
Kostenlos starten →